10x Genomics, Inc. — Director's Dealing 2020

Jul 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-07-01

Reporting Person: Hindson Benjamin J. (Director, See Remarks, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-01	Class A Common Stock	M	33750	$0.88	Acquired	101250	Direct
2020-07-01	Class A Common Stock	S	14474	$87.113	Disposed	86776	Direct
2020-07-01	Class A Common Stock	S	18065	$87.9244	Disposed	68711	Direct
2020-07-01	Class A Common Stock	S	1211	$88.67	Disposed	67500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-01	Stock Option (right to buy)	$0.88	M	33750	Disposed	2025-10-27	Class A Common Stock (33750)	Direct

Footnotes

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $86.50 to $87.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from 87.50 to $88.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $88.50 to $88.875. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: All of the shares subject to the option are fully vested and exercisable as of the date hereof.